Abbott Laboratories (ABT)vs20/20 Biolabs, Inc. Common Stock (AIDX)
ABT
Abbott Laboratories
$111.25
-0.02%
HEALTHCARE · Cap: $182.49B
AIDX
20/20 Biolabs, Inc. Common Stock
$0.55
+5.86%
HEALTHCARE · Cap: $5.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 2525243% more annual revenue ($46.59B vs $1.84M). ABT leads profitability with a 11.7% profit margin vs -279.1%. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
AIDX
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.9%
Fair Value
$73.92
Current Price
$111.25
$37.33 premium
Intrinsic value data unavailable for AIDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : AIDX
The strongest argument for AIDX centers on Price/Book.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABT profiles as a value stock while AIDX is a turnaround play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.58 — expect wider price swings.
ABT is growing revenue faster at 13.0% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 21/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?